Uniunea Europeană - cehă - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - neoplasmy prsů - antineoplastická činidla - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

Uniunea Europeană - cehă - EMA (European Medicines Agency)

roche registration gmbh  - risdiplam - svalová atrofie, spinální - jiné léky na poruchy muskuloskeletálního systému - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.

Uniunea Europeană - cehă - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - imunosupresiva - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Uniunea Europeană - cehă - EMA (European Medicines Agency)

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - imunitní séra a imunoglobuliny, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. viz kapitoly 4. 4 a 5.

Uniunea Europeană - cehă - EMA (European Medicines Agency)

roche registration gmbh  - pralsetinib - karcinom, plicní jiná než malobuněčná - antineoplastická činidla - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.

Uniunea Europeană - cehă - EMA (European Medicines Agency)

roche registration gmbh - mosunetuzumab - lymfom, folikulární - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

Uniunea Europeană - cehă - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmologické látky - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Republica Cehă - cehă - SUKL (Státní ústav pro kontrolu léčiv)

cheplapharm arzneimittel gmbh, greifswald array - 1946 klonazepam - injekční roztok - 1mg/ml - klonazepam

Uniunea Europeană - cehă - EMA (European Medicines Agency)

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - antineoplastická činidla - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.

Republica Cehă - cehă - SUKL (Státní ústav pro kontrolu léčiv)

hexal ag, holzkirchen array - 5389 monohydrÁt doxycyklinu - tableta - 100mg - doxycyklin